Drug
Vec 162
Vec 162: highest development phase Phase 2, developed by Vanda Pharmaceuticals. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Vanda Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| VEC-162 NCT00490945 | Phase 2 | Circadian Rhythm Sleep Disorders |
Latest
No recent events.
Follow Vec 162 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.